ВАЖНО! Правила приравнивания журналов, входящих в международные базы данных к журналам перечня ВАК.
Ответ на официальный запрос в ВАК журнала Кардиология.

Preview

The Role of Endothelial Dysfunction in the Development of Cardiotoxic Action of Cytostatics in Patients with Lymphoproliferative Diseases

https://doi.org/10.18087/cardio.2019.4.10251

Abstract

Understanding mechanisms of chemotherapy cardiotoxicity is an important problem due to the lack of clear understanding of its occurrence. Development of endothelial dysfunction is considered to be one of possible ways in implementation of these side effects. The analysis of endothelin-1 and e-selectin levels in 26  patients with lymphoproliferative diseases before and after the completion of the treatment program was been performed. The results of the study showed normal values of E-selectin level and increased level of endothelin-1 in the whole group of patients before treatment. After completion of chemotherapy program, in the whole group, there was a decrease of these two markers. However, values of level of endothelin-1 with vasoconstrictor effect remained high even after the end of therapy. It is imp ortant that at detailed analysis the dynamics of investigated markers in patients of older age group (median age 64 years) was associated with worsening of endothelial dysfunction.

About the Authors

D. A. Budanova
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
MD


Yu. N. Belenkov
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation


I. Ya. Sokolova
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation


O. N. Antyufeeva
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation


V. I. Ershov
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation


I. S. Ilgisonis
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation


I. Yu. Gadaev
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation


References

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. European Journal of Cancer. 2013;49(6):1374–403. DOI:10.1016/j.ejca.2012.12.027

2. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European Heart Journal. 2016;37(36):2768–801. DOI:10.1093/eurheartj/ehw211

3. Ganz WI, Sridhar KS, Ganz SS, Gonzalez R, Chakko S, Serafini A. Review of Tests for Monitoring Doxorubicin-lnduced Cardiomyopathy. Oncology. 1996;53(6):461–70. DOI:10.1159/000227621

4. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F et al. Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy. Circulation. 2015;131(22):1981–8. DOI: 10.1161/CIRCULATIONAHA.114.013777

5. Koptev V.D., Pospelova T.I., Tsirendorzhiev D.D. Functional state of vascular endothelium in patients with hematological malignancies before and after polychemotherapy. Siberian journal of Oncology. 2010;4:20–4.

6. Blix ES, Husebekk A. Raiders of the lost mark – endothelial cells and their role in transplantation for hematologic malignancies. Leukemia & Lymphoma. 2016;57(12):2752–62. DOI: 10.1080/10428194.2016.1201566

7. Giordano P, Muggeo P, Delvecchio M, Carbonara S, Romano A, Altomare M et al. Endothelial dysfunction and cardiovascular risk factors in childhood acute lymphoblastic leukemia survivors. International Journal of Cardiology. 2017;228:621–7. DOI:10.1016/j.ijcard.2016.11.025


Review

For citations:


Budanova D.A., Belenkov Yu.N., Sokolova I.Ya., Antyufeeva O.N., Ershov V.I., Ilgisonis I.S., Gadaev I.Yu. The Role of Endothelial Dysfunction in the Development of Cardiotoxic Action of Cytostatics in Patients with Lymphoproliferative Diseases. Kardiologiia. 2019;59(4):64-66. (In Russ.) https://doi.org/10.18087/cardio.2019.4.10251

Views: 1024


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)